TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07923981: AN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MARSTACIMAB PROPHYLAXIS IN ADOLESCENT AND ADULT PARTICIPANTS WITH MILD (FVIII OR FIX ACTIVITY >5% TO ≤15%) TO MODERATE (≥1% TO ≤5%) HEMOPHILIA A OR B WITHOUT INH

Sponsor: Pfizer · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 95 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT07923981 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07923981 Rescue Dossier →